However, only a proportion of patients respond to PD-1 immune checkpoint blockade, emphasizing the need for a better understanding of the underlying mechanisms of PD-1-inhibitor-mediated enhancement of the anti-tumor CD8+ T cell response (25). This evidence concerns the gene PDCD1 and neoplasm.